Vivienne Rebel - Nov 17, 2022 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
EVP, Chief Sci. & Med. Officer
Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Vivienne Rebel
Stock symbol
BIAF
Transactions as of
Nov 17, 2022
Transactions value $
$0
Form type
4
Date filed
11/22/2022, 03:49 PM
Previous filing
Nov 22, 2022
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIAF Common Stock, par value $0.007 Award $0 +7.24K +101.36% $0.00 14.4K Nov 17, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Dr. Rebel of 7,239 restricted shares of the Issuer's common stock, par value $0.007 (the "Common Stock"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 603 shares of Common Stock and the last of which will be of the remaining 606 shares of Common Stock, subject to Dr. Rebel's continuous service to the Issuer through each vesting date.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Vivienne Rebel)